Sanofi Winthrop Industrie – FDA 483, Jan 26, 2024
Sanofi Pasteur's Val De Reuil facility was cited for significant issues during an FDA inspection, including a failed aseptic process simulation due to mold contamination and subsequent requalification failures for a lyophilizer line used for US-licensed Dengvaxia® vaccine. Additionally, the firm failed to follow its own quality control procedures for deviation initiation, had unsuitable building construction in an aseptic area, and used an automatic visual inspection machine that required manual re-inspection of all rejects despite its qualification. These observations indicate serious deficiencies in aseptic processing, quality system adherence, facility design, and equipment suitability.
ID · ae7bb4eb-87e1-4cd2-81c7-7ce00b432db5
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.